3 Global Pharma Franchise, Sterile Injectables and Anti-Retroviral Ingredients Stocks With a Strong Future Roadmap: Lupin, Gland Pharma and Laurus Labs
- October 22, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Lupin, Gland Pharma and Laurus Labs: ROE of 9.9% to 23.8% and FY22 to FY26 revenue CAGR of 8.5% to 15.0%. Prices as of 21 Oct 2026.
Quick Answer
The three export-focused pharma stocks to watch are Lupin, Gland Pharma and Laurus Labs. Their return on equity ranges from 9.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Export-focused pharma stocks let investors follow companies that earn a large share of revenue from overseas customers. Lupin, Gland Pharma and Laurus Labs cover a global pharma franchise, sterile injectables and anti-retroviral ingredients.
This list covers three export-focused pharma stocks with complete current figures: Lupin, Gland Pharma and Laurus Labs. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Export-focused Pharma Stocks?
Export-focused pharma stocks are listed pharmaceutical companies that sell medicines, injectables and active ingredients to regulated and emerging markets. Their earnings depend on product approvals, plant capacity and pricing abroad.
Export-focused Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lupin | 1,964 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
| Gland Pharma | 2,935 | 49,953 | 44.2 | 36.0 | 9.9 | 0.03 |
| Laurus Labs | 2,012.5 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
On valuation, Lupin trades at a P/E below the industry P/E, while Gland Pharma and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing export-focused pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Export-focused Pharma Stocks Have a Strong Roadmap in India?
Export-focused pharma stocks have a strong roadmap in India because global healthcare systems keep seeking quality medicines at lower cost, and Indian companies are widening their range into complex and specialty products.
- Regulated market demand. Hospitals and payers abroad keep sourcing quality generics from India.
- Complex products. Injectables and specialty medicines face fewer competitors.
- Ingredient supply. Global drug makers rely on Indian plants for active ingredients.
Why Lupin Features Among These Export-focused Pharma Stocks
Among the export-focused pharma stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Why Gland Pharma Features Among These Export-focused Pharma Stocks
Among the branded and complex generic shares on this list, Gland Pharma is a Hyderabad-based maker of sterile injectable medicines and a leading contract manufacturer for global drug companies, with plants in India and Europe.
In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%.
Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0.
Roadmap: Injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
What to watch: Check new product launches and utilisation of its manufacturing capacity.
Why Laurus Labs Features Among These Export-focused Pharma Stocks
Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Lupin vs Gland Pharma vs Laurus Labs on Key Financials
The table below sets the three export-focused pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
| Gland Pharma | 4,625 | 6,747 | 9.9% | 1,027 | 15.2% |
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin combines the largest FY26 revenue at Rs 29,039 crore with the fastest revenue growth, a 15.0% compound annual rate. A useful habit with export-focused pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Lupin | 6,347 | 8,407 | 32.5% |
| Gland Pharma | 1,563 | 1,862 | 19.1% |
| Laurus Labs | 1,580 | 2,035 | 28.8% |
Key Risks to Check Before Investing in Export-focused Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these export-focused pharma stocks, the main points are: Long-term branded and complex generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Competition can lower the prices of widely available generics.
- Regulatory inspections. Plants must keep meeting the standards of global regulators.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter export-focused pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Export-focused Pharma Stocks
Export-focused pharma stocks reward investors who follow approvals, plant utilisation and product mix together. Lupin, Gland Pharma and Laurus Labs each bring depth in a different part of the export business. Based on the 21 October 2026 close, Lupin trades at Rs 1,964, Gland Pharma at Rs 2,935 and Laurus Labs at Rs 2,012.5.
Download the Univest iOS App or Univest Android App to track export-focused pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are export-focused pharma stocks?
Ans. Export-focused pharma stocks are listed pharmaceutical companies that sell medicines, injectables and active ingredients to regulated and emerging markets. Their earnings depend on product approvals, plant capacity and pricing abroad. This list looks at three of them, Lupin, Gland Pharma and Laurus Labs, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which export-focused pharma stocks are covered in this list?
Ans. This list covers Lupin, Gland Pharma and Laurus Labs. Based on the 21 October 2026 close, Lupin traded at Rs 1,964, Gland Pharma at Rs 2,935 and Laurus Labs at Rs 2,012.5. Their return on equity ranges from 9.9% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 15.0%.
Why do export-focused pharma stocks have a strong future roadmap in India?
Ans. Export-focused pharma stocks have a strong roadmap in India because global healthcare systems keep seeking quality medicines at lower cost, and Indian companies are widening their range into complex and specialty products. The main drivers are as follows. Regulated market demand. Hospitals and payers abroad keep sourcing quality generics from India. Complex products. Injectables and specialty medicines face fewer competitors. Ingredient supply. Global drug makers rely on Indian plants for active ingredients. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
How has Gland Pharma performed financially?
Ans. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0. Looking ahead, injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What risks should investors check before buying export-focused pharma stocks?
Ans. Investors should check a few risks before buying export-focused pharma stocks. Pricing pressure. Competition can lower the prices of widely available generics. Regulatory inspections. Plants must keep meeting the standards of global regulators. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of export-focused pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
